Based on reports on a potential biological relevance of silent TP53 mutations in breast cancer [11], we exploratorily added the 12 tumors in our cohort harboring a silent mutation to the “mutated” category and tested for associations with pCR, however, with no significant result (p > 0.05 each). This evidence concerns the gene TP53 and breast carcinoma.